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Thrombospondin-1 Is a Major Activator
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1996) and a wasting syndrome characterized by an in-
flammatory response targeting the heart, lung, pan-
The activity of TGF-b1 is regulated primarily extracel- creas, stomach, liver, and striated muscle that has been
lularly where the secreted latent form must be modi- attributed to an autoimmune process (Boivin et al., 1995;
fied to expose the active molecule. Here we show Diebold et al., 1995). Too much TGF-b1 can also be
that thrombospondin-1 is responsible for a significant catastrophic. Generalized overexpression causes le-
proportion of the activation of TGF-b1 in vivo. Histo- thality in utero or just after birth, and targeted overex-
logical abnormalities in young TGF-b1 null and throm- pression results in organ-specific and occasionally gen-
bospondin-1 null mice were strikingly similar in nine eralized pathology (see Border and Ruoslahti, 1992;
organ systems.Lung and pancreaspathologies similar McCartney-Francis and Wahl, 1994; Wahl, 1994).
to those observed in TGF-b1 null animals could be The major regulatory step controlling TGF-b1 activity
induced in wild-type pups by systemic treatment with takes place extracellularly (Munger et al., 1997). TGF-b1
a peptide that blocked the activation of TGF-b1 by is secreted by most cells in an inactive form that is
thrombospondin-1. Although these organs produced unable to interact with cellular receptors. Both in vitro
little active TGF-b1 in thrombospondin null mice, when and in vivo, the activity of the mature TGF-b1 is initially
pups were treated with a peptide derived from throm- masked by its noncovalent association with a dimer
bospondin-1 that could activate TGF-b1, active cyto- of its N-terminal propeptide, called latency-associated
kine was detected in situ, and the lung and pancreatic protein, LAP (Gentry et al., 1987; Bottinger et al., 1996;
abnormalities reverted toward wild type. McMahon et al., 1996). The LAP component of this small
latent complex is often disulfide-linked to separately
Introduction encoded latent TGF-b1-binding proteins, LTBPs, re-
sulting in the large latent form of TGF-b1. These latent
Transforming growth factor b (TGF-b) is a versatile forms enhance the stability of the cytokine and provide
cytokine intimately involved in cell growth, differen- a means of targeting it to matrix and to cell surfaces,
tiation, and immune modulation (reviewed in Roberts insuring a ready source for local activation (Lawrence,
and Sporn, 1988; Barnard et al., 1990; Massague, 1990; 1996).
Active growth factor can be released from either of
its latent complexes in vitro by extremes of pH or heat9 To whom correspondence should be addressed.
10 These authors contributed equally to this work. or by chaotropic agents (Brown et al., 1990) and can be
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activated in vivo by low dose gamma irradiation (Ehrhart organ systems, particularly the lung and pancreas. Sev-
et al., 1997), but none of these mechanisms seem likely eral of these similarities could be attributed directly to
to play a major role in its activation in vivo during normal TSP-1 activation of TGF-b1 because the phenotype of
growth and development. A variety of more physiologi- the TGF-b1 null mice could be pharmacologically repro-
cal treatments can also activate TGF-b1, including de- duced by treating wild-type animals with a peptide that
glycosylation, calpain, cathepsin, or plasmin proteolysis blocked the activation of TGF-b1 by TSP-1. Moreover,
(see Miyazono and Heldin, 1991; Abe et al., 1998), and a shift toward the normal phenotype occurred in the
exposure to reactive oxygen species (Barcellos-Hoff TSP-1 null animals in response to treatment with a pep-
and Dix, 1996) or to thrombospondin-1 (Schultz-Cherry tide derived from TSP-1 that activated TGF-b1.
and Murphy-Ullrich, 1993). It is not yet clear which, if
any, of these mechanisms of activation are utilized in
vivo under normal physiological conditions, although Results
plasmin has seemed the most likely (Munger et al., 1997).
Plasmin activates latent TGF-b1 by cleaving LAP (Ly- Histological Similarities between TSP-1 Null
ons et al., 1990). A detailed model of plasmin-dependent and TGF-b1 Null Animals
activation of the large latent complex has been delin- Seeking parallels that would suggest a role for TSP-1
eated in vitro (Nunes et al., 1997) to explain TGF-b1 in TGF-b1 activation in vivo, we evaluated the histopa-
activation seen in some cultured cells that involves thology of a variety of organ systems in young mouse
urokinase plasminogen activator and the mannose-6- pups that were null for TGF-b1 or for TSP-1 and com-
phosphate/insulin-like growth factor II receptor. There pared them to one another and to wild-type animals
is correlative in vivo evidence for a plasmin-dependent (summarized in Table 1). Mouse pups under 2 1/2 weeks
activation of TGF-b1 in the aortic walls of mice (Grainger of age were chosen for these experiments in order to
et al., 1994) and for mannose-6-phosphate receptor make direct comparisons of age-matched animals as
involvement in TGF-b1 activation following liver injury TGF-b1 null pups do not survive beyond about 4 weeks.
(Jirtle et al., 1991; Saperstein et al., 1994; De Bleser et As expected, there were significant differences among
al., 1996). However, the apparent failure of the plasmino- these animals, the most dramatic being the subsequent
gen-null animals to replicate the pathology of the TGF- early death of the TGF-b1 null pups. In contrast, the
b1-null animals and the recent observation that the TSP-1 null animals, although they also suffer some fetal
multisystem pathology that these mice do exhibit can wastage, live on to reproduce (Lawler et al., 1998). Not
be alleviated by removal of fibrinogen (Bugge et al., surprisingly, the autoimmune-based diffuse inflamma-
1996) suggest that plasmin can not be responsible for tion and wasting syndrome that accompanies the early
the majority of the activation of TGF-b1 in vivo under demise of the TGF-b1 null animals was not seen inTSP-1
normal physiological conditions. nulls where inflammation was maintained at a low level
Here we consider the possibility that thrombospon- in most organs (lung, liver, and pancreas) and was com-
din-1 (TSP-1) is an important activator of TGF-b1 in vivo. pletely absent from others, such as the heart. Some
TSP-1 is a large homotrimeric protein that is secreted
histological abnormalities such as the inflammation of
by many cell types (see Lahav, 1993; Bornstein, 1995).
the heart were confined to the TGF-b1 null animals.
In cell-free systems, it binds to and activates both small
Other defects were specific to the TSP-1 nulls, such as
and large latent forms of TGF-b1 (Murphy-Ullrich et al.,
the skeletal kyphosis and the excessive vascularity of1992; Schultz-Cherry et al., 1994a; Souchelnitskiy et al.,
the pancreatic islets and the dermis.1995). This plasmin-independent activation is thought
Despite these important differences, a careful histo-to be the result of a conformational change, possibly
logical analysis revealed that the pups of the two nullin the LAP (Schultz-Cherry and Murphy-Ullrich, 1993;
genotypes had markedly similar abnormalities in manySchultz-Cherry et al., 1994a; S. M. F.R. et al., submitted).
other organs (Table 1). Some of these, such as the 3-foldIt requires the presence of the central type 1 repeats of
increase in mitoses seen in the testes and gastric epithe-the TSP-1 protein (Schultz-Cherry et al., 1994b) and can
lium of both TGF-b1 and TSP-1 null pups, suggested abe reproduced by small peptides derived from one of
parallel loss of TGF-b1 inhibitory effects in mice of boththese repeats that contain amino acids KRFK (Schultz-
genotypes. For practical reasons, we have concentratedCherry et al., 1995). In activating TGF-b1, TSP-1 inter-
our more detailed subsequent analyses on two organacts with the N-terminal region of LAP, forming a trimo-
systems, the lung and the pancreas.lecular complex. Within the complex, a conformational
In the lung, there were a variety of histopathologicchange takes place that alters the immunoreactivity of
similarities between the TSP-1 null and the TGF-b1 nullTGF-b1 (Schultz-Cherry et al., 1995) and makes it acces-
pups. There were vessel abnormalities, as might be ex-sible to its receptor. Antibodies raised against LAP can
pected from the ability of both TGF-b1 (Majack, 1987;block TSP-1 binding (Yang et al., 1997; S. M. F. R. et al.,
Merwin et al., 1991) and TSP-1 (Majack et al., 1986)submitted), and in experiments containing only purified
to influence vascular smooth muscle growth. Whereascomponents, peptides derived from LAP containing the
age-matched wild-type mice had thin-walled vesselsamino acids LSKL can prevent both TSP-1 binding and
(Figure 1D) with no evidence of alveolar hemorrhageTGF-b1 activation (S. M. F. R. et al., submitted).
(Figure 1A), null animals of both genotypes had bronchi-Data presented below show that TSP-1 contributes
olar arteries that were thickened and tortuous with ansignificantly to the activation of TGF-b1 in vivo. A sys-
increased number of vascular smooth muscle cell nucleitematic comparison of the histology of young mouse
(Figures 1E and 1F). Active TGF-bs (antibodies recog-pups that were null for TSP-1 with pups null for TGF-
b1 disclosed a strikingly similar pathology in multiple nize the active form of TGF-bs 1, 2, and 3) could be
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Table 1. Comparison of Morphological Features of TSP-1 Null and TGF-b1 Null Animals
Morphological Feature Wild-Type Animals TSP-1 Null Animals TGF-b1 Null Animals
Lung
Bronchial epithelial hyperplasia 0 11 11/111
Proximal mucinous metaplasia 0 1/11 1/11
Vascular SMC hyperplasia 0 11 11/111
Clara cell hyperplasia 0/1 11 11
Inflammation 0 1/11 11/111
Pancreas
Islet cell hyperplasia 0 11 11/111
Acinar hypoplasia 0 1/11 1/11
Inflammation 0 1 11
Islet vessels/10 high-power fields 2.0 6 1.0 7.7a 6 1.5 4.3 6 1.2
Liver
Dilatation of bile ducts adjacent to distended gallbladder 0 11 1/11
Periportal acute inflammation 0 1 1/11
Kidney
Indistinct cortico-medullary junction N 11 11
Stomach
Gastric epithelial hyperplasia N 11 11
Intestinal metaplasia at G±E junction N 11 1/11
Mitoses/10 high-power fields 3.3 6 1.5 11a 6 1.5 12a 6 2.1
Testes
Nuclear atypia 0 1/11 11
Mitoses/10 high-power fields 7.3 6 1.5 21a 6 2.1 20a 6 1.2
Skin
Paucity of dermal matrix N 1/11 1/11
Excessive dermal vascular density N 1/11 N/1
Bone
Irregular bony spicules in endochondral ossification centers 0 1/11 11
Thoracic kyphosis 0 11 0
Heart
Enlarged myocytes within the ventricular septum 0 1/11 11
Inflammatory infiltrates 0 0 111
0/N, normal; 1, mild; 11, moderate; 111, severe.
a Different from wild type, p , 0.05.
detected in the vascular smooth muscle cell layer of and goblet cells, supporting a metaplastic change. In
one third of the TSP-1 null animals, mucinous secretionswild-type animals (Figure 1G) but were significantly re-
duced in TSP-1 null mice (Figure 1H). Multifocal capillary were so excessive that the larger bronchi were partially
occluded (see mucicarmine stain, Figure 2B).leakage and alveolar hemorrhage were also common
in TSP-1 null (Figure 1B) and TGF-b1 null (Figure 1C) These pulmonary changes correlated with the loss of
TSP-1 and the lack of TGF-b activation. TSP-1 (Figureanimals, although they were not seen in wild-type mice
(Figure 1A). In the TSP-1 null animals, the lung hemor- 2E) and active TGF-bs (Figure 2H) were both highly ex-
pressed in the wild-type bronchiolar epithelium, and ac-rhage was seen in areas lacking inflammatory infiltrates
and did not directly correlate with the degree of inflam- tive TGF-bs were also seen in underlying tissue. Al-
though the localization of active TGF-b may appearmation. Hemorrhage did not resolve with age since he-
mosiderin-laden macrophages were evident within alve- diffuse in these and other photos, evaluation under high
power confirmed its extracellular location. TSP-1 wasolar spaces in adult mice (Lawler et al., 1998).
Animals null for either TSP-1 or TGF-b1 also had simi- expressed well in the TGF-b1 null pups (Figure 2G). In
the TSP-1 null animals, although antibodies recognizinglar morphological disturbances in the proximal airway
where TGF-b1 is particularly highly expressed (Jetten all forms of TGF-b showed that latent TGF-bs were
clearly present in epithelial cells undergoing proliferativeet al., 1986; Zhou et al., 1996) and can induce squamous
differentiation and inhibit epithelial cell proliferation (Ma- changes (Figure 2F), the active cytokine was no longer
detected in this cell layer (Figure 2I). The stain wassui et al., 1986). The proximal segments of the lung of
both the TGF-b1 (Figures 2C and 2D) and TSP-1 (Figures clearly working properly as underlying tissue stained
well for active TGF-bs in TSP-1 null animals (Figure 2I).2B, 2F, and 2I) null animals showed hyperplasia, pleo-
morphism, and increased mitoses, which suggested the Despite the ability of antibodies specific for active
TGF-bs to recognize all three isoforms, tissue frompresence of altered proliferation as well as a possible
arrest or disturbance in differentiation. These changes TGF-b1 null animals was negative (Figure 1J), sug-
gesting that in this tissue, b1 is the dominant activewere associated with a shift in the composition of proxi-
mal airway cell types to a high number of Clara cells species.
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Figure 1. Vascular Smooth Muscle Hyperplasia and Alveolar Hemorrhage in Lungs of TSP-1 Null and TGF-b1 Null Animals
Lung tissue of wild-type mice (A, D, and G), TSP-1 null animals (B, E, and H), and TGF-b1 null animals (C, F, and I) are shown. (A)±(F) stained
with HPS and (G)±(I) for active TGF-bs (brown stain). Note the thin-walled vessels (D) with no evidence of alveolar hemorrhage in wild-type
mice (A) in contrast to the multifocal alveolar hemorrhage (B and C) and marked vascular smooth muscle hyperplasia (E and F) in both null
animals. Unboxed A indicates alveolar space; L, the lumen of blood vessel. (B) and (C), 203; (G), 1003; others, 403.
The TSP-1 and TGF-b1 null animals also showed par- In wild-type animals, TGF-b1 localized to acini (Figure
3C) as has been reported for the human pancreas (Ya-allel morphological changes in the pancreas, where
TGF-b1 is known to be critical in regulating the balance manaka et al., 1993). The strong staining for active
TGF-bs present in wild-type acini was much reduced inbetween the acinar and endocrine development (Sanvito
et al., 1994). TSP-1 expression has not previously been acini of TSP-1 null pups (Figure 3F).
observed in the pancreas, but immunoreactivity of wild-
type mice suggested that it is associated with nearly all Peptides Could Restore the Production of Active
TGF-b in Fibroblasts Cultured from TSP-1islets and a few interstitial cells (Figure 3B) and can be
seen in the matrix (evident here in Figure 3H). Compara- Null Mice and Inhibit Its Production
by Wild-Type Fibroblastsble staining was evident in pediatric human pancreatic
tissue (data not shown). All TSP-1 null animals examined If deficiencies in TGF-b1 activation contribute to the
morphological changes observed in the TSP-1 null ani-had an increased number of islet cells throughout the
organ and exhibited a relative hypoplasia of the exocrine mals, then cells derived from the TSP-1 null animals
should be less efficient than those from wild-type ani-pancreas and interstitial matrix (compare Figure 3A with
3D) that was confirmed by quantitative morphometric mals in activating latent TGF-b1. As it can be quite diffi-
cult to measure levels of active TGF-b1 in cell secretionsanalyses (Table 2). The pancreas of TGF-b1 null animals
showed similar but even more striking changes in the (Munger et al., 1997), to test this prediction we turned
to coculturing test cells directly with indicator cells.endocrine and exocrine pancreas with islet cell hyper-
plasia and moderate to severe inflammation (Figure 3G). Strains of fibroblasts derived from the dermis, where
TSP-1 Activates TGF-b1 In Vivo
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Figure 2. Bronchial Epithelial Hyperplasia and Metaplasia in TSP-1 Null and TGF-b1 Null Animals and in Peptide-Treated Pups
(A±J) Representative sections of bronchial tissue from wild-type animals (A, E, and H), TSP-1 null animals (B, F, and I), and TGF-b1 null animals
(C, D, G, and J) are shown with (B) stained for mucicarmine, (E) and (G) stained for TSP-1, (F) stained for total TGF-b, and (H), (I), and (J)
immunostained specifically for active TGF-bs. In wild-type tissue, note the single layer of uniform bronchial epithelial cells, which stain
positively for both TSP-1 (E) and active TGFb (H). In TSP-1 null and TGF-b1 null animals, bronchial epithelial hyperplasia and focal mucinous
metaplasia are evident. In TSP-1 null animals, the metaplastic epithelial cells failed to stain for active TGF-bs (I), whereas focal positivity is
present in bronchiolar smooth muscle cells and infiltrating macrophages. In comparison, antibodies that also recognize latent TGF-b1 stain
this tissue well (F). In TGF-b1 null animals, TSP-1 staining remained strong (G) and staining for active TGF-bs was absent (J).
(K±M) Proximal airway bronchial epithelium is shown from a wild-type mouse that was treated with the LSKL peptide that blocked TSP-1
activation of TGF-b1 (K) and from a TSP-1 null mouse treated with the TSP-1-derived peptide KRFK that activated TGF-b1 (L and M). (K) and
(M) were stained for active TGF-bs. Similarly stained wild-type tissue is shown in (H). Note changes in the epithelium from a single layer in
wild-type animals (A, E, and F) to a metaplastic epithelial lining with enlarged nuclei displaced by goblet-like cells in wild-type animals treated
with the blocking peptide (K). Animals lacking TSP-1 that were treated with the activating peptide reverted toward a wild-type bronchial
epithelial morphology (L) and showed strong staining for active TGF-bs (M).
All panels, 403, except (E), 203.
similar tissue changes were seen in both null animals, in low amounts that were similar to those produced by
other cultured cells (Table 3; Sato et al., 1990; Kojimawere isolated from three wild-type pups and three TSP-1
nulls and cocultured for 16 hr with a reporter cell line and Rifkin, 1993; Souchelnitskiy et al., 1995). The TSP-1
null cells activated only one eighth the amount of TGF-bharboring a TGF-b1-responsive promoter driving the ex-
pression of a luciferase reporter gene (Abe et al., 1994). that was activated by cells derived from wild-type ani-
mals. The deficit in TGF-b activation was apparently dueActive TGF-b was produced by the wild-type fibroblasts
Cell
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Table 2. Effect of Blocking and Activating Peptides on Pancreatic Morphometry
Mouse Islet Area (m2) Acinar Area (m2) Ratio (Islet/Acinar 3100)
Wild type
No treatment 1684 64,380 2.6a
1 control peptide SLLK 1398 59,110 2.4a
1 blocking peptide LSKL 2890 15,322 19
TSP-1 null
No treatment 6689 30,855 22a
1 control peptide KQFK 5688 27,892 20a
1 activating peptide KRFK 1125 17,491 6.4
Mice were treated with indicated peptide from day 3 to day 16 and areas measured from histological slides.
a These values differ significantly from the corresponding peptide treatment, p , 0.017.
to a deficit in TSP-1 because production of active TGF-b that pups all gained weight at a similar rate whether
treated with KRFK, with a cognate control peptide,could be restored to these cultures by a short peptide
derived from TSP-1 (Table 3) that has been shown to KQFK, or with PBS. Histological examination revealed
that the lungs and the pancreas of all of the KRFK-activate latent TGF-b1 in biochemically pure systems
(Schultz-Cherry et al., 1995). To verify that the TSP-1 treated pups, but none of the control animals, now had
a morphology similar to that of wild-type pups.molecule could activate the latent TGF-b produced by
TSP-1 null cells, human thrombospondin purified from Each pancreas of animals treated with the activating
peptide acquired a more normal phenotype in that theirplatelets and stripped of bound TGF-b1 activity was
tested. At concentrations from 20 to 80 nM, TSP-1 was islet area decreased relative to acinar area (Table 2;
compare Figures 3M and 3N with 3A and 3B). The aciniable to activate up to 15% of the total latent TGF-b
present in this media conditioned by TSP-1 null fibro- of the treated pups showed stronger immunoreactivity
for active TGF-b1 (Figure 3O) than those from an un-blasts in a dose-dependent manner (data not shown).
Fibroblasts cultured from wild-type animals were also treated TSP-1 null pup (Figure 3F). The lung and pancre-
atic tissues of the three pups with control peptide,examined to determine if blocking TSP-1 activation of
TGF-b would significantly decrease active TGF-b pres- KQFK, and of another three pups treated with vehicle
PBS were indistinguishable from those of untreated an-ent in their conditioned media. TSP-1 activates TGF-b1
by interacting with the latency-associated protein, and imals.
The lungs of the TSP-1 null pups treated with KRFKin purified systems this interaction is prevented by a
peptide derived from the latency-associated protein, (Figures 2L and 2M) were morphologically more similar
to those of wild-type animals (Figures 2A, 2E, and 2H)LSKL (S. M. F. R. et al., submitted). When this peptide
was added to cultured wild-type mouse fibroblasts that than to untreated TSP-1 null animals (Figures 2B, 2F,
and 2I). The epithelial cells of all KRFK-treated pupswere secreting TSP-1, the active TGF-b that accumu-
lated in their media over a 24 hr period was significantly were less pleomorphic than those of the control pep-
tide±treated animals, and their bronchial epithelium hadreduced (Table 4).
fewer stratified regions and in many areas was a single
cell layer thick as it is in wild-type pups. In contrast toTreatment of TSP-1 Null Animals with the
TSP-1-Derived Peptide that Activated the bronchial epithelial cells of TSP-1 null animals, which
were negative for active TGF-b staining (Figure 2I), epi-TGF-b1 Normalized the Pathology of
the Pancreas and the Proximal Airway thelial cells of the KRFK-treated TSP-1 null animals
stained positively for active TGF-bs (Figure 2M). OverallTo link more closely the pathology of the TSP-1 null
animals to the ability of TSP-1 to activate TGF-b1, three the inflammation in the lungs in KRFK-treated animals
improved, and aggregates of acute inflammatory cellsTSP-1 null mice were treated daily from 3 to 16 days of
age with the TSP-1-derived peptide KRFK, which acti- were no longer evident. A mild chronic inflammatory
infiltrate did persist in the peribronchial regions of thevates TGF-b1 in biochemically pure systems (Schultz-
Cherry et al., 1995) and in secretions of TSP-1 null cells lungs, but it was not consistently found in regions of
altered epithelial phenotype.(Table 3). The treatment caused no apparent toxicity in
Figure 3. Comparison of Pancreatic Morphology of Wild-Type, TSP-1 Null, and TGF-b1 Null Mice and the Effects of Specific Peptide Treatments
(Top) Pancreatic tissue from animals that were wild type (A, B, and C), TSP-1 null (D, E, and F), or TGF-b1 null (G, H, and I) stained with
HPS(A, D, and G), anti-TSP-1 (B, E, and H), or anti-active TGF-bs (C, F, and I). Islet cell hyperplasia, paucity of acinar structures, and mild
chronic inflammation are present in tissue from both null genotypes (D and G). Note expression of TSP-1 in islets of wild-type (B) and TGF-
b1 null (H) tissue and the presence of active TGF-b1 in the acini of wild-type tissue (C) that is reduced in tissue from TSP-1 nulls (F) and
absent in that from TGF-b1 nulls (I).
(Bottom) Pancreatic tissue from wild-type pups treated with the LSKL peptide that blocked TSP-1 activation of TGF-b1 (J, K, and L) and from
TSP-1 null pups treated with the KRFK peptide that activated TGF-b1 (M, N, and O), stained with HPS (J, K, M, and N) and for active TGF-
bs (L and O). In LSKL peptide-treated wild-type pups, note reduced amounts of active cytokine and abnormalities characteristic of the
untreated null animals. In tissue from KRFK peptide±treated TSP-1 null pups, note positive staining for active TGF-bs and lessening of
abnormalities. Unboxed letter I marks islets of Langerhans. (B), (C), and (H), 403; (F), (I), (L), and (O), 1003; others, 203.
Cell
1166
Table 3. Restoration of Deficits in Production of Active TGF-b Using TSP-1-Derived Peptides on Cells Cultured from TSP-1 Null Animals
Test cells Active TGF-b (pg/ml)
1. Wild-type fibroblasts 8.8 6 2.0
2. TSP-1 null fibroblasts 1.0 6 0.7
3. TSP-1 null fibroblasts 1 activating peptide KRFK 8.3 6 1.5
4. TSP-1 null fibroblasts 1 inactive peptide KQFK 1.5 6 0
5. No fibroblasts 1 activating peptide KRFK 1.3 6 1.3
6. No fibroblasts 1 inactive peptide KQFK 0.8 6 0.8
Dermal fibroblasts were cocultured in the presence or absence of peptides at 50 mM with indicator cells containing luciferase under a TGF-
b-sensitive promoter, and luciferase production that was sensitive to TGF-b-neutralizing antibodies was measured after 16 hr. Standard errors
are indicated. 1 different from 2, p , 0.008; 3 different from 4, p , 0.03.
Treatment of Wild-Type Animals with a LAP Peptide active TGF-bs, prominent in wild-type acinar tissue (Fig-
ure 3C), was reduced in the treated pups (Figure 3L).that Blocks TSP-1 Activation of TGF-b1 Produced
Lung and Pancreatic Phenotypes Similar The pancreas and the bronchial epithelium of the three
pups treated with a control peptide, SLLK, and an addi-to Those Seen in Null Animals
In an experiment parallel to that described above, three tional three treated with vehicle PBS did not differ mor-
phologically orhistologically from the untreated animals.wild-type animals were treated with a peptide, LSKL,
derived from that portion of the of TGF-b1 latency-
associated protein (LAP) that interacts with TSP-1 and Discussion
curtails TSP-1 activation of TGF-b1 in pure systems
(S. M. F. R. et al., submitted) as well as in complex- Data presented above demonstrate that TSP-1 is an
important natural activator of TGF-b1 in the lung and inconditioned media (Table 4). When examined histologi-
cally, theproximal airway epithelium of the LSKL-treated the pancreas where both molecules were expressed
and where parallel abnormal pathologies were seen inwild-type pups resembled that of the TSP-1 null and
TGF-b1 null pups (Figure 2K). It showed focal metaplasia animals null for either one of the two proteins. The histo-
logical changes seen in these null mice can be attributedwith enlarged nuclei displaced by goblet-like cells, an
increased number of Clara cells, and multifocal acute to lack of activation of TGF-b1 by TSP-1, for they could
be reproduced in wild-type pups with a peptide thatand chronic inflammatory infiltrates. Staining for active
TGF-bs that was seen clearly in untreated wild-type blocked TSP-1 activation of TGF-b1 in vitro and reduced
the presence of active cytokine in vivo, and they wereanimals (Figure 2H) was lost in the bronchial epithelial
cells of treated pups (Figure 2K), although areas around ameliorated in TSP-1 null pups by a TSP-1-derived pep-
tide that activated TGF-b1 in vitro and produced activeunderlying smooth muscle and macrophages remained
positive. cytokine in vivo. As the peptides were injected IP, it is
possible that TGF-b1 was activated IP and circulatedIn the pancreas of LSKL-treated animals, qualitative
and quantitative increases in the number of islet cells from there to the lung and pancreas, although its short
half-life and our ability to stain the active cytokine inwere seen (Figure 3J; Table 2). In all three animals, there
was focal dropout of acinar structures (Figure 3K), al- situ in peptide-treated animals aremore compatible with
its being activated locally in individual organs. The simi-though it did not approach the degree of hypoplasia or
inflammatory-related destruction noted in the pancre- larities between the two null pups extended over multi-
ple organs, suggesting that TGF-b1 activated by TSP-1atic tissue of the TGF-b1 null animals. In 2 of the 3
peptide-treated animals, a mild chronic inflammatory also contributes to the normal development of the tes-
tes, bone, kidney, liver, heart, skin, and stomach. TSP-1infiltrate was found in the pancreas that was composed
of predominantly lymphocytes (Figure 3K) and was simi- also may influence the hematopoeitic systems as both
null animals also have increased white blood cell countslar to that found in both null animals. Reactivity with
Table 4. Effect of Inhibitory Peptide on Media Conditioned by TSP-1-Producing Cells
Cell Strains Agar Colonies/0.5 ml Conditioned Media
Untreated 1 Inhibitory Peptide 1 Control Peptide
Control LSKL SLLK
A1 63 70 108
A2 102 78 117
A6 119 74 104
A18 104 69 84
Mean 97 6 12 73 6 2a 103 6 7
Serum-free media conditioned for 24 hr in the presence or absence of 1 mM peptide by four independently derived wild-type fibroblast cultures
were assayed in triplicate for active TGFb using the NRK agar colony formation assay. Heat activation of untreated controls resulted in total
TGF-b1 sufficient to induce 191 6 13 agar colonies/0.5 ml conditioned media. Control of 35 for media plus BSA has been subtracted from
all values. Standard error of the mean is indicated.
a Different from control peptide, p , 0.02.
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skewed toward monocytes, a smaller thymus, an abnor- TSP-1 in cultured cells derived from vascular smooth
muscle and lung epithelium (Penttinen et al., 1988; Ma-mal spleen, and hypercellular bone marrow (data not
shown; Shull et al., 1992; Boivin et al., 1995; Lawler et jack et al., 1990; Laiho et al., 1991; RayChaudhury et al.,
1994), both tissues that showed in vivo abnormalities.al., 1998).
Although the antibodies used to stain for active The animal studies presented above suggest several
parallels to human disease. In the pancreas, TGF-b1 isTGF-b1 recognize all three TGF-bs, and TSP-1 is able
to activate both TGF-b1 and TGF-b2 in a manner inhibit- known to stimulate insulin secretion and to block the
mitogenic response of pancreatic b cells to glucoseable by the inactivating peptide LSKL (S. M. F. R. et al.,
submitted), most of the abnormalities we observed in (Sjoholm and Hellerstrom, 1991), raising the possibility
that the pancreatic changes seen in the null mice maythe TSP-1 null animals and in wild-type animals treated
with the inactivating peptide appeared to be specific for represent precursor lesions to insulin-dependent diabe-
tes mellitus or glucose instability. In the lung, the abnor-TGF-b1, for they were present in the TGF-b1 null animals
and have not been reported in the TGF-b2 or TGF-b3 malities seen in both null mice are very reminiscent of
the persistent inflammation, mucinous metaplasia, andnull mice (Kaartinen et al., 1995; Proetzel et al., 1995;
Sanford et al., 1997), and no active cytokine staining vascular smooth muscle cell hyperplasia that to varying
degrees characterize a variety of pulmonary diseaseswas seen in the lung or pancreas of TGF-b1 null pups
(Figures 2J and 3I). It is likely that TSP-1, but not other including asthma and cystic fibrosis. The identification
of TSP-1 as a particularly effective activator of TGF-b1TSP family members, is activating TGF-b1. TSP-2 is the
family member most similar to TSP-1, but despite one in the lung and the pancreas and the ability of small
peptides to modify its effects in vivo suggest new routesreport that a preparation enriched for TSP-2 can activate
TGF-b1 (Souchelnitskiy et al., 1995), TSP-2 lacks the that might be considered to interfere with the progres-
sion of such diseases.essential KRFK sequences, and when recombinantly
produced, it has no such activity (Schultz-Cherry et al.,
1995). Experimental Procedures
TSP-1 is the first activator of TGF-b1 shown to func-
Animalstion in natural, untreated, nondiseased tissues in vivo,
TSP-1 null animals (Lawler et al., 1998) and TGF-b1 null animalsyet mice must have additional ways to produce the ac-
(Shull et al., 1992) were both generated by homologous recombina-
tive cytokine, for TSP-1 null pups avoid the autoimmune tion in 129/Sv-derived ES cells implanted into C57/BL6 blastocysts
destruction and the early death of the TGF-b1 nulls. followed by backcrossing with C57/BL6 animals and inbreeding the
Even in the lungs of TSP-1 null pups, light focal staining F1. For morphological studies, we examined 9 TSP-1 null animals
that were 17 days old and 4 TGF-b1 null mice aged 10±21 days,for active cytokine was seen, although it was much less
both on a mixed C57/Bl6/Sv129 background, 6 TSP-1 null animalsintense than in comparable tissue from wild-type ani-
on a Sv129 background, 4 wild-type Sv129 mice, 9 wild-type C57/mals. Active TGF-b1 in TSP-1 null mice could be the
BL6, and 4 C57/Bl6/Sv129 F1 hybrids within these age brackets.
result of an alternate activation pathway or of the direct Five adult wild-type, TSP-1 null, and TGF-b1 heterozygous animals
release of active cytokine by some cells, as has been and six 1-month-old individuals were also evaluated. Histology was
suggested for B cells and plasma cells (Caver et al., consistent among all wild-type animals, and abnormalities seen in
null animals wereobserved in all individuals examined within a single1996). The pathology of the TGF-b1 null pups suggests
genotype.that their early death is related to local TGF-b1 defi-
For peptide treatments, 3-day-old TSP-1 null animals were ran-cits in specific organs, most likely the heart. It was se-
domized into three groups of three animals each, to receive 14
verely compromised by inflammation in the TGF-b1 nulls consecutive days of treatment consisting of intraperitoneal injection
whereas the hearts of the TSP-1 nulls who live on to with 100 mg peptide/day of either KRFK, a TSP-1-derived TGF-b1-
reproduce were free of inflammation. activating peptide (Schultz-Cherry et al., 1995); KQFK, an inactive
control peptide (Schultz-Cherry et al., 1995); or vehicle alone (PBS).Just as TGF-b1 has other activators, TSP-1 has a
Three-day-old wild-type mice were treated identically with eithervariety of other functions that do not seem to depend
LSKL, a peptide that blocks TSP-1 activation of TGF-b (S. M. F. R.on its ability to activate TGF-b1 (Bornstein, 1995). It is
et al., submitted); SLLK, an inactive control peptide (S. M. F. R. et
one of the most potent natural inhibitors of angiogenesis al., submitted); or vehicle alone (PBS).
identified to date (Dawson and Bouck, 1998). Its ability Animals were monitored daily, and no differences were observed
to block the migration of endothelial cells in vitro and in general appearance, coat consistency, or body weight between
peptide-treated and vehicle-treated animals. Animalssacrificed withto inhibit experimentally induced neovascularization in
an overdose of metafane underwent gross and microscopic exami-vivo have been shown to be independent of the activa-
nations. Peptides were synthesized by the University of Alabamation of TGF-b1 (Tolsma et al., 1993; Dawson et al., 1997).
Comprehensive Cancer Center/Peptide Synthesis and Analysis fa-This independence can now be extended to its negative
cility and purified by HPLC as described (Lioubin et al., 1991).
influence on the natural development of small vessels,
for the TSP-1 null animals had increased vessel densities Microscopic Examination
in the dermis and in the pancreatic islets that were not Organs were individually dissected, fixed in 10% buffered formalin
seen in the TGF-b1 null pups. overnight, processed, and embedded in paraffin. Livers were evalu-
ated using a section that included the gall bladder, hearts withTSP-1 activation of TGF-b1 seems well suited to sup-
sections taken immediately below the atrioventricular valves, andply the low but persistent levels of active TGF-b1 impor-
kidneys with sections that included the renal pelvis and a smalltant in normal growth and development. TSP-1 activated
portion of the ureter, and ossification centers were observed at the
only a portion of the latent TGF-b1 available either in cell sternocostal junction and in one limb. Slides were prepared and
secretions as shown here or in pure systems (Schultz- stained with either H and E (hematoxylin and eosin), HPS (hematoxy-
Cherry and Murphy-Ullrich, 1993), yet it has the opportu- lin-phloxine-saffarin for fibrous tissue), PAS (periodic acid±Schiff),
or mucicarmine (for mucin-secreting cells). Although TGF-b1 nullnity to form an amplifying loop. TGF-b1 can induce
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